Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Pro-Inflammatory Cytokines of Non-Healing and Healing Cutaneous Leishmaniasis Publisher Pubmed



Moafi M1 ; Rezvan H1 ; Sherkat R2 ; Taleban R2 ; Asilian A3 ; Hamid Zarkeshesfahani S4 ; Nilforoushzadeh MA5 ; Jaffary F3 ; Mansourian M6 ; Sokhanvari F3 ; Ansari N3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pathobiology, Faculty of Veterinary Science, Bu-Ali Sina University, Hamedan, Iran
  2. 2. Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran
  5. 5. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Scandinavian Journal of Immunology Published:2017


Abstract

Cutaneous leishmaniasis (CL) heals spontaneously within several weeks or months, but, in rare cases, CL-active lesions last for many years. In this study, we assessed cell-mediated immunity in non-healing CL through the measurement of three pro-inflammatory cytokines: Interferon-γ (IFN-γ), IL-17a and CXCL-11. For this, 32 patients afflicted with healing or non-healing CL were recruited in this study. Peripheral blood mononuclear cells (PBMCs) of every patient were treated with three antigens: purified protein derivative (PPD), soluble Leishmania antigen (SLA) and phytohaemagglutinin (PHA). Cytokine quantification was performed using enzyme-linked immunosorbent assay (ELISA) method. Results of our study showed that neither cytokine produced in the presence of a PPD stimulator (as an irrelevant antigen) significantly differed between the healing and non-healing groups (P-value ≥0.05 for all of them). However, IFN-γ, CXCL-11 and IL-17a levels produced in the presence of PHA or SLA were significantly higher within the healing than in the non-healing group (P-value <0.01 for all of them). It seems that appropriate levels of IFN-γ, as well as IL-17a and CXCL-11, contribute to the control of Leishmania infection. © 2017 The Foundation for the Scandinavian Journal of Immunology
Related Docs
View other Related Docs
1. Study of Il-12 Agonists in Macrophages From Patients With Healing and Non-Healing Forms of Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2013)
2. Evaluation of Il-12Rb1, Il-12B, Cxcr-3 and Il-17A Expression in Cases Affected by a Non-Healing Form of Cutaneous Leishmaniasis: An Observational Study Design, BMJ Open (2017)
3. The Comparison of the Ifn-ɤ, Tnf-Α and Il-10 Cytokines in Healing and Non-Healing Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2021)
4. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
5. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
6. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
7. Il-23 and Il-27 Levels in Macrophages Collected From Peripheral Blood of Patients With Healing Vs Non-Healing Form of Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
8. Comparison of Immune Regulatory Factors in Acute and Chronic Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Research in Medical Sciences (2014)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (44)
Ali Asilian (13)
Other Related Docs
9. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Isfahan Medical School (2014)
10. Tlr2 and Tlr4 in Cutaneous Leishmaniasis Caused by Leishmania Major, Scandinavian Journal of Immunology (2013)
11. Exposure to Leishmania Major Modulates the Proportion of Cd4+ T Cells Without Affecting Cellular Immune Responses, Microbiology and Immunology (2007)
12. Immune Response Measured in Human Volunteers Vaccinated With Autoclaved Leishmania Major Vaccine Mixed With Low Dose of Bcg, Clinical and Experimental Immunology (2003)
13. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Research in Medical Sciences (2012)
14. Anti-Leishmaniasis Effect of Staphylococcus Aureus Protein a on the Size of the Lesion and Parasitic Load, Advanced Biomedical Research (2023)
15. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
16. Comparison of Protein Profile of Killed and Autoclaved Leishmania Major Using Polyacrylamide Gel Electrophoresis, Journal of Isfahan Medical School (2013)
17. Cutaneous Leishmaniasis Reinfection: Skin Disease and Leishmaniasis Research Center, Isfahan, Iran, Journal of Isfahan Medical School (2015)
18. The Effects of Prednisolone and Mometasone on Wound Healing Caused by Leishmania Major in Balb/C Mice, Journal of Isfahan Medical School (2020)
19. Visceral Leishmaniasis in a Patient With Cutaneous Lesions, Negative Leishman-Donovan Bodies and Immunological Test: A Case Report, Journal of Research in Medical Sciences (2011)
20. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran, Archives of Iranian Medicine (2020)
21. Effect of Acupuncture Treatment on Level of Serum Interferon (Ifn)-Γ in Balb/C Model of Leishmania Major Infection, Journal of Isfahan Medical School (2013)
22. Evaluation of Leishmanin Skin Test and Its Relationship With the Clinical Form and Duration of Cutaneous Leishmaniasis, Dermatology Online Journal (2006)
23. Comparative Effect of Topical Trichloroacetic Acid and Intralesional Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, International Journal of Pharmacology (2006)
24. Evaluation of Leishmanin Skin Test Reaction in Different Variants of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2013)
25. Identification of Leishmania Isolates From Healing and Nonhealing Cutaneous Leishmaniasis Patients Using Internal Transcribed Spacer Region Pcr, Jundishapur Journal of Microbiology (2014)
26. Effect of Topical Honey Application Along With Intralesional Injection of Glucantime in the Treatment of Cutaneous Leishmaniasis, BMC Complementary and Alternative Medicine (2007)
27. The Efficacy of 5% Trichloroacetic Acid Cream in the Treatment of Cutaneous Leishmaniasis Lesions, Journal of Dermatological Treatment (2012)
28. Recombinant C-Reactive Protein: A Potential Candidate for the Treatment of Cutaneous Leishmaniasis of Balb/C Mice Caused by Leishmania Major, Acta Parasitologica (2021)
29. Anti-Leishmania Activity of Osthole, Pharmacognosy Research (2016)
30. Distribution Frequency of Pathogenic Bacteria Isolated From Cutaneus Leishmaniasis Lesions, Korean Journal of Parasitology (2008)
31. A Lentiviral Vaccine Expressing Kmp11-Haspb Fusion Protein Increases Immune Response to Leishmania Major in Balb/C, Parasitology Research (2018)
32. In Vitro Anti-Leishmanial Activity of Satureja Hortensis and Artemisia Dracunculus Extracts on Leishmania Major Promastigotes, Journal of Parasitic Diseases (2016)
33. Topical Effectiveness of Different Concentrations of Nanosilver Solution on Leishmania Major Lesions in Balb/C Mice, Journal of Vector Borne Diseases (2012)
34. Cutaneous Necrosis After the Injection of Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis: A Rare Case Report, Journal of Isfahan Medical School (2019)
35. Treatment of Cutaneous Leishmaniasis: Cassia Fistula Fruit Gel-Intralesional Glucantime Vs. Placebo Gel- Intralesional Glucantime Combination, Tehran University Medical Journal (2010)
36. Comparison of Intralesionally Injected Zinc Sulfate With Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, Dermatology (2004)
37. Therapeutic Effect of Topical Tamoxifen in Murine Cutaneous Leishmaniasis Caused by Leishmania Major, Antimicrobial Agents and Chemotherapy (2024)
38. A Randomised, Double-Blind, Controlled Trial of a Killed L. Major Vaccine Plus Bcg Against Zoonotic Cutaneous Leishmaniasis in Iran, Vaccine (1999)
39. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)
40. Nramp1 Gene Polymorphisms and Cutaneous Leishmaniasis: An Evaluation on Host Susceptibility and Treatment Outcome, Journal of Vector Borne Diseases (2016)
41. Bacterial Superinfection in Zoonotic Cutaneous Leishmaniasis, Medical Science Monitor (2012)
42. Electrocardiographic Changes in Patients With Cutaneous Leishmaniasis Treated With Systemic Glucantime, Annals of the Academy of Medicine Singapore (2008)
43. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2013)
44. The Study of the Inhibitory Effects of Aqueous and Ethanolic Extracts of Ziziphora Tenuior L. on the Proliferation of Leishmania Major Amastigotes, Iranian Journal of Dermatology (2018)
45. The Skin Side Effects of Topical Glucantime in Patients With Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2015)
46. Effect of Adjunctive Topical Liposomal Azithromycin on Systemic Azithromycin on Old World Cutaneous Leishmaniasis: A Pilot Clinical Study, Iranian Journal of Pharmaceutical Research (2021)
47. Cd137: A Member of the Tnfr Family - in Psoriasis Skin Lesions in Comparison With Normal Skin Specimens, Iranian Journal of Pathology (2021)
48. Locked Nucleic Acid -Anti- Let-7A Induces Apoptosis and Necrosis in Macrophages Infected With Leishmania Major, Microbial Pathogenesis (2018)
49. Study of Therapeutic Effect of Different Concentrations of Imatinib on Balb/C Model of Cutaneous Leishmaniasis, AIMS Microbiology (2020)
50. Evaluation of Anti-Desmoglein 1 Antibody in Cutaneous Leishmaniasis Patients, Journal of Isfahan Medical School (2012)